Summary
78 / 100 · Bulios Score
What speaks for it
- Earnings per share grew by 39% a year over the last 3 years.
- Out of every 100 USD of revenue, 25 USD is left as net profit.
- It has raised its dividend 14 years in a row and pays out only 33% of profit.
- Analysts expect revenue to grow by 11% this fiscal year.
What to watch
- The share price is above the Bulios Fair Price.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 28.7 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 14% a year over 5 years. Over the last 3 years it grew by 16% a year. For the next fiscal year analysts expect revenue to grow by 11%. Earnings per share grew by 39% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 27 USD
- Research and development 5.9 USD
- Sales and administration 38 USD
- Taxes and other 4.4 USD
- Net profit 25 USD
Net profit, industry median (Medical - Instruments & Supplies) 8.1 USD
Out of every 100 USD of revenue, 25 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesRepaying all its debt would take 2.6 years of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
Small, safe- Yield
- 1.15%
- Paid out of profit
- 33%
- Raised in a row
- 14 years
You receive $0.95 per share a year. The company covers the payout with ease.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 14
- Hold 6
- Sell 0
Today's price within the analysts' price targets
The average target of $115 is 36% above today's price. 70% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
The company reports no revenue by product.
By region
- Americas 64%
- EMEA 29%
- Asia Pacific 6.7%
Americas brings in 64% of revenue. EMEA grew fastest, by 15% a year.
Segments in detail